Study of two drugs for advanced esophageal or stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced esophageal squamous cell carcinoma or stomach/gastroesophageal junction adenocarcinoma that cannot be removed by surgery and has spread.
- Your cancer has gotten worse after first-line treatment with an anti-PD-1 drug plus chemotherapy, and you were on that treatment for at least 3 months without it getting worse.
- You are in generally good health (able to care for yourself, up and about more than 50% of waking hours).
- You have at least one tumor that can be measured on scans and has not been treated with radiation.
- You have adequate organ function (kidney, liver, blood cells) as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two immunotherapy drugs and a targeted antibody-drug before standard treatment for locally advanced cervical cancer. The goal is to see if this triple therapy can shrink tumors more effectively before surgery or radiation.
This study tests a new combination of drugs (sacituzumab tirumotecan plus others) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination works better for those who have not had treatment before or whose cancer progressed after one line of therapy.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.